Evidence mapPaperPMID 40745466Full record

Trial reportNature metabolism2025

Combining a diet rich in fermentable carbohydrates with metformin improves glycaemic control and reshapes the gut microbiota in people with prediabetes.

Natural H S Chu, James Ling, Emily W M Poon, Jimmy Y S Lee, Qianbo Song, Zhong Zuo, Jane Muir, Juliana C N Chan, Elaine Chow

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Nature metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05628584. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05628584 nacompleted

The Impact of High or Low FODMAP Diets on Postprandial Glucose Response and Gut Microbiota in Individuals With Prediabetes Treated With Metformin: A Randomized Crossover Controlled-Feeding Trial

Ran2022Enrolled26Registered outcomes7Posted comparisons0ConditionsImpaired Glucose Tolerance, PrediabetesArmsHigh FODMAP diet with metformin, Low FODMAP diet with metformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Natural H S ChuDepartment of Medicine and Therapeutics, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong SAR, China.
James LingDepartment of Medicine and Therapeutics, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong SAR, China.
Emily W M PoonDepartment of Medicine and Therapeutics, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong SAR, China.
Jimmy Y S LeeDepartment of Gastroenterology, School of Translational Medicine, Monash University and Alfred Health, Melbourne, Victoria, Australia.ORCID http://orcid.org/0009-0005-3434-1326
Qianbo SongSchool of Pharmacy, the Chinese University of Hong Kong, Hong Kong SAR, China.
Zhong ZuoSchool of Pharmacy, the Chinese University of Hong Kong, Hong Kong SAR, China.
Jane MuirDepartment of Gastroenterology, School of Translational Medicine, Monash University and Alfred Health, Melbourne, Victoria, Australia.
Juliana C N ChanDepartment of Medicine and Therapeutics, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong SAR, China.ORCID http://orcid.org/0000-0003-1325-1194
Elaine ChowDepartment of Medicine and Therapeutics, Prince of Wales Hospital, the Chinese University of Hong Kong, Hong Kong SAR, China. e.chow@cuhk.edu.hk.ORCID http://orcid.org/0000-0002-4147-3387

Funding

Chinese University of Hong Kong (CUHK) RFS2223/0621/23Innovation and Technology Commission (ITF) MRP 029/21Merck KGaA NA
6 · The paper itself

Abstract

Metformin efficiently lowers blood glucose levels but leads to gastrointestinal side effects. However, whether dietary interventions can improve metformin tolerability and glucose-lowering efficacy remains unknown. Here we investigate the effects of pretreatment with a diet rich in fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) in combination with metformin on postprandial glycaemia and gut microbiota in people with prediabetes. In a double-blind, randomised, crossover trial, 26 individuals with prediabetes received an isocaloric diet with moderate or low FODMAPs for 10 d, concomitantly with metformin for 5 d, separated by a washout period of 2 weeks. The primary endpoint is the difference in postprandial glycaemia assessed by total postprandial incremental area under the curve through continuous glucose monitoring. Secondary endpoints are differences in glucose, insulin and glucagon-like peptide 1 (GLP-1) levels after an oral glucose tolerance test, gut microbiota, gastrointestinal symptoms and body weight. We show that moderate FODMAPs with metformin, as compared with low FODMAPs with metformin, result in lower postprandial glycaemia, higher GLP-1 secretion and higher Butyricimonas virosa abundance. We also show that a higher baseline abundance of Dorea formicigenerans predicts gastrointestinal intolerance to metformin. These findings have implications for personalizing nutritional and pharmacological interventions to prevent diabetes. ClinicalTrials.gov registration: NCT05628584 .

Indexed as

Dietary CarbohydratesGastrointestinal MicrobiomeGlycemic ControlHypoglycemic AgentsMetforminPrediabetic StateAdultAgedBlood GlucoseCross-Over StudiesDouble-Blind MethodFemaleFermentationHumansMaleMiddle AgedBlood GlucoseDietary CarbohydratesHypoglycemic AgentsMetformin

Identifiers

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.